Ramadan in UAE: Less sleep can cause lack of concentration, accidents, experts say
Loss of sleep during Ramadan could cause several health issues including lack of concentration and even cause accidents, according to experts. One doctor explained that many people suffer from insufficient sleep syndrome during the month.
'What people are suffering from Ramadan is mostly insufficient sleep syndrome,' said Dr. Mutaz Labib, Consultant Pulmonary and Critical Care Disease and head of Sleep Lab at Clemenceau Medical Center Hospital. 'They wake up late and have sleep disruption during the month. So, in the morning, they suffer symptoms like lack of concentration, memory problems, fatigue, tiredness, laziness and urge to nap during the daytime.'
He added that previous studies have shown that loss of sleep could contribute to causing accidents as people tend to fall asleep at the wheel.
Many of those who fast during Ramadan, often wake up before dawn to eat the pre-fasting meal called Suhoor. Factors like special nightly Tharaweeh prayers and family gatherings often contribute to the lack of sleep among UAE residents.
Data from 2024
Wearable company Whoop said that their 2024 data showed a drop in sleep performance and recovery scores during the month of Ramadan as compared to the previous month. A recovery score tells how ready the body is to handle stress each day.
'Good sleep is the key to recovery and performing well,' said Stephan Muller, the company's GCC Marketing Director. 'Changes in daily routines during Ramadan, such as later bedtimes and early mornings, affected Whoop members' sleep patterns with data showing they slept fewer hours and experienced less consistent sleep, likely playing a role in lower recovery scores.'
He added that during Ramadan, recovery scores were also impacted by changes in eating, drinking, and sleep routines making it harder for the body to restore and recharge.
However, he added that the strain recorded for Whoop users was lower during Ramadan as compared to the pre-Ramadan period. "Strain measures how much effort your body puts in throughout the day,' he said. 'During Ramadan, people naturally took it easier — likely adjusting workouts and daily movement to match changes in eating and sleep schedules."
Warning signs
Dr. Mutaz said that people should watch out for warning signs which could be caused as a result of lack of sleep. 'If you have snoring, and especially loud snoring, that's a big sign it could be something that needs attention,' he said. 'Most of our clients are brought in by their wives because if you sleep alone, no one knows whether you're snoring or not. So that is a task on partners.'
He added that the tendency to have excessive daytime napping should also be taken seriously. 'When you have excessive daytime sleepiness or tiredness, you must go and see a specialist,' he said. 'During a sleep study, we attach electrodes to the brain and heart. We also attach an EMG line to measure the muscle activity overnight and place sensors in the nose and mouth to check breathing. So sleep study is really a health test. It can discover a lot of things.'
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Emirates Woman
4 days ago
- Emirates Woman
Fasting for Ramadan: 5 key tips to nourish your body and soul
Fasting during Arafat Day is a significant spiritual practice for Muslims around the world. It involves abstaining from food and drinks from dawn until sunset, on the day before Eid Al Adha. While fasting, individuals focus on prayer, reflection, and self-discipline. Here are five tips to help make fasting on Arafat Day a spiritually fulfilling and physically manageable experience. Hydration is Key Begin your fast with a balanced suhoor meal that includes plenty of fluids and hydrating foods such as fruits and vegetables. Drink plenty of water during non-fasting hours to prevent dehydration. Avoid caffeine and sugary drinks, as they can cause thirst. Eat Nutritious Foods Opt for wholesome, nutrient-rich meals during iftar (breaking the fast) to replenish your body's energy levels. Include complex carbohydrates, lean proteins, and healthy fats to sustain you throughout the fasting period. Avoid overeating or indulging in heavy, greasy foods, which can lead to discomfort and sluggishness. Moderate Physical Activity While intense exercise may be challenging during fasting hours, light physical activity such as walking or gentle stretching can help maintain energy levels and promote overall well-being. Listen to your body and avoid strenuous activities, especially during the hottest parts of the day. Prioritize Rest and Sleep Ensure you get adequate rest and sleep during Ramadan to support your body's fasting process. Aim for seven to eight hours of sleep per night and consider taking short naps during the day if needed. Establish a bedtime routine to promote relaxation and quality sleep. Focus on Spiritual Growth Use the opportunity of Ramadan to deepen your connection with your faith. Allocate time each day for spiritual reflection and self-improvement. Engage in community iftars and taraweeh prayers to foster a sense of unity and solidarity with fellow Muslims. – For more on luxury lifestyle, news, fashion and beauty follow Emirates Woman on Facebook and Instagram Images: Pexel & Unsplash, Feature Image: Instagram @futurebedouin
Gulf Today
5 days ago
- Gulf Today
elegant hoopoe Spotlights GCC Franchise Investment with Strategic Expansion
DUBAI, UAE – Esteemed weight loss and aesthetics clinic, elegant hoopoe, today announced a pivotal strategic move into franchising across the Gulf Cooperation Council (GCC), with a pronounced emphasis on the dynamic UAE market. This initiative is strategically designed to elevate the brand's social proof and capture heightened investor interest in its continued growth narrative. Mr. Shahriar Shahir Barzegar, the Founder and CEO of elegant hoopoe, has successfully guided the Dubai-based company to its current position of operational strength. With three flourishing branches already serving a discerning clientele, the brand has validated its business model and demonstrated significant market appeal for its specialized, high-end services. Further underscoring its expansionary vision, elegant hoopoe is advancing with plans for new clinic inaugurations in two key UAE locales: Abu Dhabi and Damac Hills. These developments are crucial components of the company's strategy to enhance the accessibility of its signature client experience, which harmoniously blends a welcoming ambiance with elegant and aspirational service delivery. "Our strategic entry into franchising is a transformative step for elegant hoopoe," remarked Mr. Shahriar Shahir Barzegar. "We have meticulously engineered a scalable and successful operational blueprint that consistently delivers superior client results within a sophisticated clinic setting. We are now inviting forward-thinking investors and partners who resonate with our vision to introduce elegant hoopoe's acclaimed services to a wider audience across the GCC. This is more than expansion; it's about cementing a leadership position as a credible and sought-after brand in the wellness and aesthetics landscape." The long-range strategy for elegant hoopoe is focused on achieving significant market presence and brand recognition throughout the GCC. Central to this is a franchise model developed to provide robust support to partners, offering a transparent and effective framework for operational success and investor value. elegant hoopoe is committed to empowering its franchisees with the comprehensive tools and in-depth knowledge necessary to consistently deliver its high service standards. This targeted franchising program is poised to attract investors and strategic allies eager to collaborate with a progressive brand dedicated to making meaningful contributions to personal wellbeing and aesthetic enhancement. elegant hoopoe remains firmly dedicated to principles of sustainable growth, unwavering brand integrity, and the delivery of exceptional value to its clients and franchise network. About elegant hoopoe: elegant hoopoe is a leading clinic in weight loss and aesthetics, headquartered in Dubai, UAE. Founded by Mr. Shahriar Shahir Barzegar, the clinic offers a curated selection of specialized services, enabling clients to achieve their wellness and aesthetic goals within a uniquely welcoming, elegant, and aspirational setting. With a steadfast commitment to innovation and client-centric care, elegant hoopoe is strategically positioned for significant growth and market leadership across the GCC. Discover more at .
Arabian Business
5 days ago
- Arabian Business
Inside Insilico's bid to create the UAE's first homegrown cancer drug
Clinical-stage biotech company Insilico Medicine recently announced it will attempt to discover the first novel cancer drug developed entirely in the United Arab Emirates with just four scientists and its proprietary AI platform to complete work that traditionally takes hundreds of researchers and years of effort. The Abu Dhabi-based team aims to identify promising cancer targets, design new molecules, and prepare a complete preclinical data package within 18 months—a process that typically takes pharmaceutical companies three to five years and costs hundreds of millions of dollars. 'Our Masdar City centre already hosts around 60 AI and biotech specialists. By tasking four of them with a complete end-to-end discovery run, we aim to prove that any GCC nation equipped with cloud compute, wet-lab automation and local talent can create world-class therapeutics,' Alex Zhavoronkov, PhD, founder and CEO of Insilico Medicine, told Arabian Business. The initiative represents both a scientific experiment and a geopolitical statement as it has the potential to transform the Middle East's role in global pharmaceutical development while challenging fundamental assumptions about where and how drug discovery can occur in the AI era. Four scientists, one AI The team consists of two computational chemists, one medicinal chemist, and one translational biologist – a deliberately lean operation working alongside Insilico's proprietary AI system, They are targeting what the company describes as 'medium-novelty and genetically validated synthetic-lethality targets' for solid tumours –essentially, seeking ways to kill cancer cells by exploiting specific genetic vulnerabilities. In pharmaceutical terms, the team is working at breakneck speed. Their roadmap calls for finalising a biological target by Q3 2025, generating promising molecular structures in under 30 days, and completing the entire preclinical package within 18 months. Traditional drug discovery typically takes three to five years just to reach the preclinical stage. 'Humans still design strategy and verify results, but AI handles the brute-force search, learns from every experiment in real time, and steers us away from dead ends,' explained Zhavoronkov. His description evokes a chess grandmaster working with a silicon partner—humans providing intuition and judgment, the machine crunching through billions of possibilities. Why the UAE? The choice of Abu Dhabi might seem puzzling at first. The UAE has invested heavily in healthcare infrastructure, but it remains far from established biotech hubs like Boston, San Francisco, or Cambridge. For Zhavoronkov, that's precisely the point. 'The reason we chose the UAE is because we already have a base there,' he said, referring to the AI Research and Development Centre that Insilico opened in Masdar City in 2023 with support from the Abu Dhabi Investment Office. 'UAE scientists helped discover a drug but they never tried to take full control over the drug discovery program.' This initiative – which Zhavoronkov is careful to note is self-funded by Insilico, not UAE government money – is as much about proving a concept as it is about discovering a specific drug. If a small team in Abu Dhabi can successfully identify a viable cancer treatment, it suggests that any country with sufficient computing resources and a small cadre of specialists could potentially develop life-saving medications. 'Not just lucky' Insilico's approach builds on research dating back to 2016, when the company published one of the first papers describing how generative adversarial networks (GANs) – the same AI architecture later used in image generators like DALL-E – could design novel molecules. The biotech landscape is littered with AI companies that promised to revolutionise drug discovery but delivered little. Zhavoronkov seems acutely aware of this skepticism. 'Since 2021 we have nominated 22 development candidates, advanced 10 into the clinic, completed four Phase I trials and a Phase IIa – without a single clinical failure,' he said. 'Those numbers convert skepticism into evidence.' Asked why Insilico has succeeded where others have not, Zhavoronkov pointed to four specific factors: 'Pristine, well-curated data – quantity without quality is noise; a closed experimental loop where every prediction is rapidly tested in-house and fed back to the models; deep integration of AI engineers, biologists and chemists under one roof… and many experimentally-validated AI models that we know worked in real world.' In an industry where approximately 90 per cent of drug candidates fail during development, Insilico's lead drug, Rentosertib, recently showed positive results in a Phase IIa trial for idiopathic pulmonary fibrosis (a serious lung disease that causes scarring of the lungs). The company reported that Rentosertib demonstrated favourable safety and tolerability across all dose levels, with promising early efficacy signals after just 12 weeks of treatment. In January 2025, Nature Biotechnology published a paper detailing Rentosertib's journey from AI algorithms to clinical trials – the first comprehensive account of an AI-discovered and AI-designed drug from initial concept to human testing. The company is already planning to expand across the Gulf region. Insilico recently signed a Memorandum of Understanding with Saudi Arabia's Ministry of Investment and plans to establish an operation in Riyadh by 2026, with partial funding from Aramco's Prosperity7 Ventures. The company is also in discussions with Qatar, Kuwait, Bahrain, and Oman about potential expansion. 'If the pilot hits its timelines, we will deploy identical micro-teams across the region, accelerating the sovereign drug-discovery capabilities where it matters most,' Zhavoronkov said. The bigger picture Beyond regional implications, Insilico's experiment touches on a profound question: does drug discovery still need massive teams, extensive physical infrastructure, and geographical proximity to traditional biotech clusters? 'The goal is to have multiple AI-originated drugs approved and on pharmacy shelves, with a steady stream of new candidates entering the clinic every year,' he said. '[For Insilico Medicine,] success looks like regulators, payers and physicians treating AI-designed medicines as the norm – much like jetliners are now designed in silico.' Alex Aliper, Co-Founder and President of Insilico Medicine, framed the effort in economic terms, suggesting that channelling the Gulf's 'deep technology' investments into 'life-saving medicines offers the fastest way to diversify economies and extend healthy longevity' in the region.
